Logo image of BMEA

BIOMEA FUSION INC (BMEA) Stock Fundamental Analysis

NASDAQ:BMEA - Nasdaq - US09077A1060 - Common Stock - Currency: USD

1.81  -0.1 (-5.24%)

After market: 1.81 0 (0%)

Fundamental Rating

1

Taking everything into account, BMEA scores 1 out of 10 in our fundamental rating. BMEA was compared to 557 industry peers in the Biotechnology industry. BMEA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. BMEA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BMEA had negative earnings in the past year.
BMEA had a negative operating cash flow in the past year.
In the past 5 years BMEA always reported negative net income.
BMEA had a negative operating cash flow in each of the past 5 years.
BMEA Yearly Net Income VS EBIT VS OCF VS FCFBMEA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

The Return On Assets of BMEA (-233.63%) is worse than 91.38% of its industry peers.
BMEA has a Return On Equity of -447.60%. This is in the lower half of the industry: BMEA underperforms 77.38% of its industry peers.
Industry RankSector Rank
ROA -233.63%
ROE -447.6%
ROIC N/A
ROA(3y)-98.37%
ROA(5y)-65.2%
ROE(3y)-137.7%
ROE(5y)-89.02%
ROIC(3y)N/A
ROIC(5y)N/A
BMEA Yearly ROA, ROE, ROICBMEA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 0 0 0 0

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BMEA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BMEA Yearly Profit, Operating, Gross MarginsBMEA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for BMEA has been increased compared to 1 year ago.
The number of shares outstanding for BMEA has been increased compared to 5 years ago.
There is no outstanding debt for BMEA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BMEA Yearly Shares OutstandingBMEA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
BMEA Yearly Total Debt VS Total AssetsBMEA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -16.45, we must say that BMEA is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of BMEA (-16.45) is worse than 82.23% of its industry peers.
There is no outstanding debt for BMEA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -16.45
ROIC/WACCN/A
WACCN/A
BMEA Yearly LT Debt VS Equity VS FCFBMEA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M 150M

2.3 Liquidity

A Current Ratio of 2.25 indicates that BMEA has no problem at all paying its short term obligations.
BMEA's Current ratio of 2.25 is on the low side compared to the rest of the industry. BMEA is outperformed by 72.89% of its industry peers.
A Quick Ratio of 2.25 indicates that BMEA has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.25, BMEA is doing worse than 70.92% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.25
Quick Ratio 2.25
BMEA Yearly Current Assets VS Current LiabilitesBMEA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 0.56% over the past year.
EPS 1Y (TTM)0.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.61%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, BMEA will show a small growth in Earnings Per Share. The EPS will grow by 6.65% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y40.68%
EPS Next 2Y22.29%
EPS Next 3Y17.17%
EPS Next 5Y6.65%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BMEA Yearly Revenue VS EstimatesBMEA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2030 2031 2032 200M 400M 600M 800M 1B
BMEA Yearly EPS VS EstimatesBMEA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BMEA. In the last year negative earnings were reported.
Also next year BMEA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BMEA Price Earnings VS Forward Price EarningsBMEA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BMEA Per share dataBMEA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

BMEA's earnings are expected to grow with 17.17% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.29%
EPS Next 3Y17.17%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BMEA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOMEA FUSION INC

NASDAQ:BMEA (6/20/2025, 8:18:21 PM)

After market: 1.81 0 (0%)

1.81

-0.1 (-5.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-05 2025-05-05/amc
Earnings (Next)07-31 2025-07-31/amc
Inst Owners56.44%
Inst Owner Change-6.92%
Ins Owners6.9%
Ins Owner Change0%
Market Cap68.00M
Analysts81.43
Price Target20.4 (1027.07%)
Short Float %32.38%
Short Ratio4.62
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-7.21%
Min EPS beat(2)-28.2%
Max EPS beat(2)13.79%
EPS beat(4)3
Avg EPS beat(4)-0.66%
Min EPS beat(4)-28.2%
Max EPS beat(4)13.79%
EPS beat(8)5
Avg EPS beat(8)0.42%
EPS beat(12)6
Avg EPS beat(12)-2.71%
EPS beat(16)6
Avg EPS beat(16)-7.34%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-20%
PT rev (3m)-33.88%
EPS NQ rev (1m)-1.59%
EPS NQ rev (3m)41.26%
EPS NY rev (1m)-2.37%
EPS NY rev (3m)33.5%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.37
P/tB 2.37
EV/EBITDA N/A
EPS(TTM)-3.55
EYN/A
EPS(NY)-1.94
Fwd EYN/A
FCF(TTM)-3.03
FCFYN/A
OCF(TTM)-3.02
OCFYN/A
SpS0
BVpS0.76
TBVpS0.76
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -233.63%
ROE -447.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-98.37%
ROA(5y)-65.2%
ROE(3y)-137.7%
ROE(5y)-89.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 18.21%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.25
Quick Ratio 2.25
Altman-Z -16.45
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)130.81%
Cap/Depr(5y)432.09%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.61%
EPS Next Y40.68%
EPS Next 2Y22.29%
EPS Next 3Y17.17%
EPS Next 5Y6.65%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y3.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-0.65%
EBIT Next 3Y3.1%
EBIT Next 5Y2.21%
FCF growth 1Y-41.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-48.46%
OCF growth 3YN/A
OCF growth 5YN/A